HOYA Vision Care Announces New Sensity® 2 Light-Adaptive Lenses with Nearly Twice the Fadeback Speed

Advanced lens technology offers nearly twice the fadeback speed of its first generation Demand for light-adaptive lenses increases as two-thirds of patients now report sensitivity

Ophthalmic lens technology leader HOYA Vision Care announced today the next generation of its popular Sensity light-adaptive lenses. Two out of every three eyecare patients experience light sensitivity, making light-adaptive lenses a convenient and comfortable everyday vision solution for most patients.

A significant improvement compared to the previous generation of Sensity lenses, Sensity 2 lenses offer nearly twice the fadeback speed – approximately 42 percent faster.

Building on more than five years of success with its first-generation Sensity® lenses, HOYA Vision Care has created a product that rapidly darkens to a category 3 sun lens tint, fades back nearly twice as fast to a clear lens indoors, and still offers the same comfort, convenience, and protection as the entire Sensity family – with 100% UV protection, reduced glare from the sun when activated, and blue light protection indoors and outdoors2.

Available today, Sensity 2 lenses come in three intense natural color options: Silver Grey, Bronze Brown, and Emerald Green. They are compatible with HOYA’s Single Vision, Backside Progressives, and iD designs, as well as all of HOYA’s current antireflective treatments.

Two key technological innovations underlie the improved performance of the lenses: Stabilight Technology provides consistent performance and UV protection no matter the climate, cold or warm. Precision Technology ensures a microscopically accurate spin-coating process, creating superior adhesion for great scratch resistance.

“We are excited to bring Sensity 2 lenses to the market, offering an even faster fadeback that ECPs and their patients will greatly benefit from,” said Nick LaManna, Director of Product Management for HOYA Vision Care, North America. “Our continuous focus on improving our products has made us an industry leader in light-adaptive lens technology, and these are no exception.”

Interested ECPs can ask their HOYA Territory Sales Manager for more information about Sensity 2 light-adaptive lenses. Additionally, Visionary Alliance members are eligible to earn points when they choose Sensity 2 for their patients’ vision needs.


1. Harris Interactive Consumer Market Research Study, Global Report, Nov 2019: Usage Behavior When Outdoors

2. Based on internal testing of average light transmission between 381nm-500nm compared to standard clear lens

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”